556556/566 ISSN 2358-291X (Online) Cad. Saúde Colet., 2020;28(4):556-566 | https://doi.org/10.1590/1414-462X202028040484 Original Article This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cost analysis of hemophilia treatment in a Brazilian public blood center Custo-análise do tratamento da hemofilia em um hemocentro público brasileiro Adriana Aparecida Ferreira 1,2 , Igor Vilela Brum 3 , João Vítor de Lanna Souza 3 , Isabel Cristina Gonçalves Leite 4  1 Serviço de Hematologia, Hospital Universitário, Universidade Federal de Juiz de Fora (UFJF) - Juiz de Fora (MG), Brasil. 2 Hemocentro Regional de Juiz de Fora, Centro de Hematologia e Hemoterapia de Minas Gerais, Fundação HEMOMINAS - Juiz de Fora (MG), Brasil. 3 Faculdade de Medicina, Universidade Federal de Juiz de Fora (UFJF) - Juiz de Fora (MG), Brasil. 4 Programa de Pós-graduação em Saúde e em Saúde Coletiva, Universidade Federal de Juiz de Fora (UFJF) - Juiz de Fora (MG), Brasil. How to cite: Ferreira AA, Brum IV, Souza JVL, Leite ICG. Cost analysis of hemophilia treatment in a Brazilian public blood center. Cad Saúde Colet, 2020;28(4):556-566. https://doi.org/10.1590/1414-462X202028040484 Study carried out at Hemocentro Regional de Juiz de Fora – Juiz de Fora (MG), Brasil. Correspondence: Adriana Aparecida Ferreira. E-mail: adriana.hemato@gmail.com Financial support: none. Conflict of interests: nothing to declare. Received on: Oct. 09, 2018. Accepted on: Oct. 20, 2019 Abstract Background: hemophilia is a rare coagulopathy, treated by replacing the missing blood clotting factor. Objective: to assess the direct costs of hemophilia treatment from the perspective of the Unified Health System, highlighting the impact costs of new therapeutic modalities. Method: partial economic assessment of the direct costs of hemophilia, in which were collected data from patient records from 2011 to 2015, at the Blood Center in the city of Juiz de Fora. Costs were assigned to consultations, exams, hospitalizations, and medications according to the price list of the National Health Surveillance Agency (in Portuguese ANVISA) and the Table of Procedures, and Medications. Results: among 98 patients evaluated, 76 had hemophilia A, and 43.3% presented severe hemophilia. The number of consultations and the consumption of Clotting Factor Concentrates (CFCs) were higher in severe hemophilia. Hospitalizations were rare. Direct costs increased 286.8% from 2011 to 2015. The mean annual cost per patient was R$57,416.43, with no significant difference between hemophilia A and B. The expenditures for factor concentrates amounted to 99.46% of total costs. The actual impact cost was more than R$6,000,000.00. Conclusion: the direct costs of hemophilia were high, mainly due to factor concentrates. There was an increase in costs with the incorporation of technologies, although there are some areas with potential inefficiencies. Keywords: hemophilia A; hemophilia B; costs and cost analysis; joint diseases. Resumo Introdução: hemofilia é uma coagulopatia rara, tratada com reposição do fator de coagulação deficiente. Objetivo: avaliar custos diretos do tratamento da hemofilia pela perspectiva do Sistema Único de Saúde brasileiro, destacando o impacto nos custos das novas modalidades terapêuticas. Método: análise econômica parcial dos custos diretos da hemofilia. Foram coletados dados de prontuários de pacientes do Hemocentro de Juiz de Fora de 2011-2015. Aos atendimentos, exames, hospitalizações e medicamentos, foram atribuídos custos conforme as Tabelas de Preços da Agência de Vigilância Sanitária e de Procedimentos e Medicamentos do SUS. Resultados: entre 98 pacientes avaliados, 76 tinham hemofilia A e 43,3%, hemofilia grave. O número de consultas e o consumo de concentrados de fatores da coagulação foram mais altos na hemofilia grave. Hospitalizações foram raras. Os custos diretos aumentaram 286,8% entre 2011-2015. O custo anual médio por paciente foi R$57.416,43 sem diferença significativa entre